High Failure Rate of a Decellularized Osteochondral Allograft for the Treatment of Cartilage Lesions
Purpose: To report on functional outcomes and graft survivorship for patients receiving a “sterilized and decellularized osteochondral allograft” (Chondrofix; ZimmerBiomet) implant for knee cartilage injuries.
- Chondrofix - a pre-shaped, sterilized and decellularized osteochondral allograft implant, was introduced as an alternative to fresh osteochondral allografts
- Two surgeons from two institutions implanted Chondrofix in 32 patients, making this the largest study to report outcomes on the implant
- Twenty-three of the 32 knees, or 72%, were considered failures due to structural damage diagnosed by arthroscopy or MRI and any reoperation that resulted in the removal of the graft
- The implant survivorship was 19.6% at 2 years
- There was no significant difference in outcomes between patients who had previously underwent other surgical treatment and those who had the implant as their first procedure
- Age was a significant predictor of failure with a hazard ratio of 1.68 per 1 standard deviation older than the mean (35.1 + 10.6 years)
- Histologic analysis on Chondrofix plugs removed during a revision procedure demonstrated that very few cells were present and the majority of cartilage was devoid of cells
Take Away: With a 72% failure rate within the first two years of implantation at two institutions, the Chondrofix implant does not exhibit similar outcomes to fresh osteochondral allografts.
Authors: Jack Farr, Guilherme C. Gracitelli, Nehal Shah, Eric Y. Chang and Andreas H. Gomoll
Published: The American Journal of Sports Medicine
Level of Evidence: IV
Institution: OrthoIndy Hospital, Indianapolis, Indiana and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
Click here to read the entire abstract.